[Federal Register Volume 78, Number 114 (Thursday, June 13, 2013)]
[Notices]
[Page 35637]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-14036]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Prospective Grant of Exclusive License: Modulation of Poliovirus 
Replicative Fitness by Deoptimization of Synonymous Codons

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i) that the Technology Transfer Office, Centers for 
Disease Control and Prevention (CDC), Department of Health and Human 
Services (HHS), is considering granting an exclusive license, in the 
field of use of vaccine targets for treatment or prevention of diseases 
in human health and in animal health, to practice the inventions listed 
in the patent applications referred to below to Codagenix Inc., having 
a place of business in Stony Brook, New York. The patent rights in 
these inventions have been assigned to the government of the United 
States of America. The patent applications(s) to be licensed are:

    US Provisional Application 60/617,545, filed 10/8/2004, entitled 
``Modulation of Poliovirus Replicative Fitness by Deoptimization of 
Synonymous Codons''; PCT Application PCT/US05/036241, filed 10/7/
2005, entitled ``Modulation of Poliovirus Replicative Fitness by 
Deoptimization of Synonymous Codons''; US National Stage Application 
11/576,941, filed 11/19/2007, entitled ``Modulation of Poliovirus 
Replicative Fitness by Deoptimization of Synonymous Codons''; and 
all related continuing and foreign patents/patent applications for 
the technology family. CDC Technology ID No. I-025-04.

    Status: Pending.
    Priority Date(s): 10/8/2004.
    If granted, the licensee will pay CDC royalties in accordance with 
the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

Technology

    Infections by intracellular pathogens such as viruses, bacteria and 
parasites, are cleared in most cases after activation of specific T 
cellular immune responses that recognize foreign antigens and eliminate 
infected cells. Vaccines against those infectious organisms have been 
traditionally developed by administration of whole live attenuated or 
inactivated microorganisms. Although research has been performed using 
subunit vaccines, the levels of cellular immunity induced are usually 
low and not capable of eliciting complete protection against diseases 
caused by intracellular microbes. However, CDC inventors discovered 
that replacement of one or more natural (or native) codons in a 
pathogen with synonymous non-preferred codons can decrease the 
replicative fitness of the pathogen, thereby attenuating the pathogen. 
The non-preferred synonymous codon(s) encode the same amino acid as the 
native codon(s), but have nonetheless been found to reduce a pathogen's 
replicative fitness. This invention teaches compositions and methods 
that can be used to develop attenuated vaccines having well-defined 
levels of replicative fitness and enhanced genetic stabilities.

DATES: Only written comments and/or applications for a license which 
are received by CDC on or before July 15, 2013 will be considered.

ADDRESSES: Requests for a copy of these patent applications, inquiries, 
comments, and other materials relating to the planned license should be 
directed to Donald Prather, J.D., Ph.D., Technology Licensing and 
Marketing Specialist, Technology Transfer Office, Centers for Disease 
Control and Prevention (CDC), 4770 Buford Highway, Mailstop K-79, 
Atlanta, GA 30341, Telephone: (770) 488-8612; Facsimile: (770) 488-
8615; Email: [email protected].

SUPPLEMENTARY INFORMATION: Applications for a license filed in response 
to this notice will be treated as objections to the giving of the 
planned license. Comments and objections submitted in response to this 
notice will not be made available for public inspection, and, to the 
extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: June 7, 2013.
J. Ronald Campbell,
Director, Division of Executive Secretariat, Centers for Disease 
Control and Prevention.
[FR Doc. 2013-14036 Filed 6-12-13; 8:45 am]
BILLING CODE 4163-18-P